Gosset Ownership
Private
Therapeutic Areas
Stage
Other
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Shanghai Cell Therapy Group General Information
Shanghai Cell Therapy Group is developing innovative cellular therapies for cancer and age-related diseases. Its lead program, BZDS‑1901, a bispecific CAR-T targeting mesothelin and PD‑1 for mesothelin-positive neoplasms, is in Phase 1 clinical trials. Another program targeting glioma has been discontinued. The company leverages expertise in stem cell rejuvenation and immune modulation to address oncology and anti-aging indications.
Contact Information
Drug Pipeline
No pipeline data available
Key Partnerships
No major pharmaceutical partnerships publicly disclosed as of June 2025.
Shanghai Cell Therapy Group Funding
No funding data available
To view Shanghai Cell Therapy Group's complete valuation and funding history, request access »